Abstract
Nonalcoholic fatty liver disease (NAFLD) affects about 20%-30% of the general population, and its clinical relevance arises from the fact that 20%-30% of these subjects develop non-alcoholic steatohepatitis (NASH), a condition at risk of cirrhosis progression. In addition NAFLD, and in particular NASH patients, are also at high risk of cardiovascular alterations, suffering overall from an increased liver and no liver-related events of risk and death. At the moment liver biopsy is the gold standard for a correct evaluation of NASH and fibrosis among NAFLD patients. However, the high and increasing prevalence of NAFLD has triggered an intensive search for alternative and non-invasive methods for evaluating disease severity. Specifically we can distinguish two main groups of non-invasive methodologies, namely ‘serum markers’ that use clinical and/or biochemical variables, and methodologies derived from elaboration of parameters arising from liver imaging techniques. All these tools showed encouraging results, even though their utility in clinical practice in the individual patients is still under debate. Therefore further efforts are needed in order to generate non-invasive algorithms that correctly assess liver damage in NAFLD patients. In particular, it should be interesting to perform gender-specific analysis, by combining old and new tools, with the aim to generate more accurate scores. Finally we think that non-invasive scores should not only be able to correctly classify the severity of liver disease in NAFLD patients, but also predict liver and non-liver related morbidity and mortality, further acting as time-dependent markers of liver and systemic disease activity. This review summarizes the present knowledge on noninvasive diagnosis in NAFLD patients, and suggest future directions for this complex research area.
Current Pharmaceutical Design
Title:Non Invasive Indexes for the Assessment of Patients with Non-alcoholic Fatty Liver Disease
Volume: 19 Issue: 29
Author(s): Salvatore Petta, Aase Handberg and Antonio Craxi
Affiliation:
Keywords: HCV, STEATOSIS, CD36.
Abstract: Nonalcoholic fatty liver disease (NAFLD) affects about 20%-30% of the general population, and its clinical relevance arises from the fact that 20%-30% of these subjects develop non-alcoholic steatohepatitis (NASH), a condition at risk of cirrhosis progression. In addition NAFLD, and in particular NASH patients, are also at high risk of cardiovascular alterations, suffering overall from an increased liver and no liver-related events of risk and death. At the moment liver biopsy is the gold standard for a correct evaluation of NASH and fibrosis among NAFLD patients. However, the high and increasing prevalence of NAFLD has triggered an intensive search for alternative and non-invasive methods for evaluating disease severity. Specifically we can distinguish two main groups of non-invasive methodologies, namely ‘serum markers’ that use clinical and/or biochemical variables, and methodologies derived from elaboration of parameters arising from liver imaging techniques. All these tools showed encouraging results, even though their utility in clinical practice in the individual patients is still under debate. Therefore further efforts are needed in order to generate non-invasive algorithms that correctly assess liver damage in NAFLD patients. In particular, it should be interesting to perform gender-specific analysis, by combining old and new tools, with the aim to generate more accurate scores. Finally we think that non-invasive scores should not only be able to correctly classify the severity of liver disease in NAFLD patients, but also predict liver and non-liver related morbidity and mortality, further acting as time-dependent markers of liver and systemic disease activity. This review summarizes the present knowledge on noninvasive diagnosis in NAFLD patients, and suggest future directions for this complex research area.
Export Options
About this article
Cite this article as:
Petta Salvatore, Handberg Aase and Craxi Antonio, Non Invasive Indexes for the Assessment of Patients with Non-alcoholic Fatty Liver Disease, Current Pharmaceutical Design 2013; 19 (29) . https://dx.doi.org/10.2174/1381612811319290004
DOI https://dx.doi.org/10.2174/1381612811319290004 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment
Current Vascular Pharmacology Biomarkers of Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD), A Review of Published Patents and Patent Applications
Recent Patents on Biomarkers Synthesis of Cyclodextrin-based Adsorbents and its Application for Organic Pollutant Removal from Water
Current Organic Chemistry Thiazoles and Thiazolidinones as Antioxidants
Current Medicinal Chemistry The Influence of Obese Insulin-Resistance on the Outcome of the Ischemia/Reperfusion Insult to the Heart
Current Medicinal Chemistry Synergistic Effect of Inhibitors of MMPs and ROS-dependent Modifications of Contractile Proteins on Protection Hearts Subjected to Oxidative Stress
Current Pharmaceutical Design Therapeutic Management Strategies for Type 2 Diabetes
Current Diabetes Reviews Preliminary Screening Indicates Promising Antimicrobial Properties of the Stem Bark Extracts of Macaranga rosea
Anti-Infective Agents Effects of Verbascoside Administration on the Blood Parameters and Oxidative Status in Jennies and Their Suckling Foals: Potential Improvement of Milk for Human Use
Endocrine, Metabolic & Immune Disorders - Drug Targets The Therapeutic Potential of Stem Cells in Amyotrophic Lateral Sclerosis
Current Signal Transduction Therapy Small Molecule Inhibitors of NF-κB and JAK/STAT Signal Transduction Pathways as Promising Anti-Inflammatory Therapeutics
Mini-Reviews in Medicinal Chemistry Reactive Oxygen Species, Vascular Disease and Cardiovascular Surgery
Current Vascular Pharmacology The Challenges of Blood Pressure Control in Dialysis Patients
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Permeation Studies of Captopril Transdermal Films Through Human Cadaver Skin
Current Drug Delivery The Genetic Background of Cholesterol Gallstone Formation: An Inventory of Human Lithogenic Genes
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Interactions Between Plasma Proteins and Naturally Occurring Polyphenols
Current Drug Metabolism Recent Advances on Neural Tube Defects with Special Reference to Valproic Acid
Endocrine, Metabolic & Immune Disorders - Drug Targets Eplerenone, a New Selective Aldosterone Blocker
Current Pharmaceutical Design Food and Food Supplements with Hypocholesterolemic Effects
Recent Patents on Food, Nutrition & Agriculture Sol Gel Method Performed for Biomedical Products Implementation
Mini-Reviews in Medicinal Chemistry